• Careers
  • ZOLL Patient Management Network Login
  • About Us
    •
  • For Patients

    For Patients

    Learn about your ZOLL medical product

  • For Medical Professionals

    For Medical Professionals

    Explore our portfolio of solutions for cardiac patient management

  • Support
    •
  • For Patients

    For Patients

  • For Medical Professionals

    For Medical Professionals

  • Support
  • Careers
  • ZOLL Patient Management Network Login
  • About Us
  • Country

    Country

    •
  • For Medical Professionals
  • LifeVest
    • zoll-life-vest

    20+ years of clinical evidence. 1M+ patients protected globally.1

    The world’s most used, studied, and proven wearable cardioverter defibrillator (WCD).2,3

    LEARN MORE CONTACT US
    man wearing LifeVest sitting outside accompanied with young child
  • Outcomes
  • How LifeVest Works
  • Guidelines
  • Actionable Insights
  • FAQs
  • Extensive Patient Support

    • Proven to reduce mortality with RCT data

    As seen in the 2020 VEST per-protocol analysis, patients that wore LifeVest® realised significant mortality reductions in the first 90 days after a cardiac event.4

    EXPLORE LIFEVEST OUTCOMES
    graph depicting LifeVest Data: 75% relative risk reduction in death, any cause graph displaying LifeVest data: 62% relative risk reduction in arrhythmic death

    20+ years of evidence across 1M+ patients globally1
    90 percent one-year survival infographic
    LifeVest Clinical Evidence 23.4 hours/day median daily wear time graphic
    LifeVest Clinical Evidence Zero median false alarms at 90 days infographic

    How LifeVest works: Performance meets comfort

    How does the LifeVest Wearable Defibrillator work?

    The LifeVest wearable cardioverter defibrillator (WCD) protects patients at risk of sudden cardiac death (SCD), when a patient’s condition is changing and permanent SCD risk has not been established.

    LifeVest is designed to detect VT/VF and, if needed, automatically deliver a treatment shock to restore normal heart rhythm.
    Chart displaying an Example Detection and Treatment sequence of the LifeVest wearable cardioverter defibrillator for VF

    Timely defibrillation with an AI-enhanced algorithm

    The LifeVest TruVector™ detection algorithm uses AI-enhanced Advanced Arrhythmia Detection (AArD) technology to quickly and accurately detect VT/VF (at a default VT threshold of 150 bpm).

    In a typical situation, the entire event, from detection to treatment, occurs in about one minute.

    The next generation LifeVest Garment

    Continuous optimisation of the LifeVest design has led to a median real-world Wear Time® of 23.4 hours/day.6

    Patients rate the newest LifeVest garment as even more comfortable, compared to the previous version.8

    Explore more innovations for better outcomes

     

    LifeVest WCD guideline recommendations

    ESC & Society guidelines

    Guidelines from the European Society of Cardiology (ESC) and American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) include recommended use of the wearable cardioverter defibrillator (WCD) for a wide range of patients at risk for SCD, including ischaemic and non-ischaemic.

    • NICM and ICM patients with heart failure are categorised with a class IIb (level B) recommendation in the ESC HF guidelines (2021)9
    • The recommendation for secondary prophylaxis remains class IIa (level C)9
    • For patients awaiting a heart transplant, the recommendation remains Class IIb (Level C)10
    MORE LIFEVEST GUIDELINES

    Actionable insights for better outcomes
    ZOLL Patient Management Network ICONS

    1 in 14 patients experience an arrhythmia while wearing LifeVest.11

    Through ZOLL Patient Management Network, LifeVest provides actionable insights about your patient during cardiac recovery to help you achieve a range of treatment goals, including:

    • Optimisation of medical therapy
    • Assess progress during recovery
    • More productive telehealth and follow-up
    • Timely clinical interventions, from ablation to ICD selection
    EXPLORE LIFEVEST INSIGHTS

    Frequently Asked Questions

    How does LifeVest work?

    LifeVest is designed to detect certain life-threatening rapid heart rhythms and, if needed, automatically deliver a treatment shock to restore normal heart rhythm. Timely defibrillation is the single most important factor to save a patient that is experiencing a rapid, life-threatening arrhythmia. A treatment shock must be delivered within a few minutes after an event to be effective; with each passing minute, a patient’s chances of survival drops 10 percent. LifeVest does not require bystander intervention. In a typical situation, the entire event, from detecting a life-threatening rapid heartbeat to automatically delivering a shock, occurs in about one minute.

    What type of patient is the LifeVest WCD appropriate for?

    LifeVest is prescribed by a doctor as part of the continuum of care for patients at risk for SCD. LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, or before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk for SCD.

    Patient support
    iStock-1161415041

    An experienced WCD support team at your side

    ZOLL has supported more than 1M LifeVest patients globally over 20+ years. Our extensive support network is here to help your patients with every step of their LifeVest journey:

    • In-person training and support
    • Representatives with extensive care experience
    • 24/7 multilingual support
    PATIENT RESOURCES

    Support of your patients

    It is very important to us to ensure that you and your patients have a positive experience with LifeVest®. We support patients and their families from the time of prescription until the time when protection from sudden cardiac death is no longer needed and the LifeVest® can be dispensed.

    24/7 Patient Emergency Hotline

    Telephone hotline around the clock, 365 days a year. All important questions are answered directly and personally.

    Training of patients

    Comprehensive training for patients and relatives and adjustment of the LifeVest® by certified specialist staff on site. The training is designed to provide all the necessary information to enable the patient to wear the device and interact with it optimally. This training is repeated as required. Patients and relatives can find further information such as training videos and answers to frequently asked questions on our website (www.lifevest.zoll.com).

    Replacement of system components

    If necessary, the components of the LifeVest® can be replaced within one working day. Our customer service is in direct contact with the patient for this purpose.

    Reimbursement of costs

    The defibrillator vest has been listed in the GKV-Spitzenverband’s list of medical aids since 2015 and is therefore regularly reimbursed by the payers. In July 2019, the list of medical aids was updated to include all primary prophylaxis with a severely impaired pumping function (LVEF ≤35%).

    Collection & Sustainability

    If the LifeVest® is no longer required during the course of the patient’s treatment, we coordinate the return of the device with the patient and their relatives. At the end of its service life, the wearable cardioverter defibrillator undergoes a comprehensive and certified reprocessing process. This process is subject to the current quality standards and the requirements of the Medical Devices Act.

    1. Based on commercial data as of November 2022.
    2. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol. 2010;56(3):194–203.
    3. Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post myocardial infarction. J Am Coll Cardiol. 2013;62(21):2000–2007early post-myocardial infarction. J Am Coll Cardiol. 2013 Nov 19;62(21):2000-7.
    4. Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;1–10. https://doi.org/10.1111/jce.14404.
    5. Kutyifa V, Moss A, Klein H, et al. One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. https://doi.org/10.1111/pace.13448
    6. Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
    7. Arkles J, Delaughter C, D’Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023 https://doi.org/10.1007/s10840-023-01497-w
    8. Data on file, 20c1184_a01. Garment Comparative Wear Test.
    9. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14;: PMID: 34447992.
    10. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC), European Heart Journal, 2022;, ehac262, https://doi. org/10.1093/eurheartj/ehac262
    11. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.

    Contact a Product Expert

    ZOLL is ready to assist you in meeting your care goals. The team that has protected globally 1M+ LifeVest patients over 20+ years now provides a suite of solutions. Connect with an expert for personalised support.

    CONTACT US     Medical professionals looking at a tablet in hospital hallway